Although preliminary regulatory-led analyses of post-marketing data have not found conclusive evidence of a causal link [14], and in the absence of evidence from large, randomised clinical trials, observational studies adequately designed to assess the comparative safety of treatments, employing an active comparator, new user design, are warranted to evaluate the risk of SIS in individuals treated with GLP-1RA
Acyl-carnitines have previously shown to be reliable biomarkers in the diagnosis or prediction of disease 18,55 such as type 2 diabetes and atypical myopathy
S.DonovanL
Compounded medications are prepared per individual prescription and are not themselves FDA-approved as drugs
Currently, topical corticosteroids, calcineurin inhibitors, and antihistamines remain the mainstay treatments for AD
Many ACA Marketplace plans manage the costs associated with GLP-1 drugs by only covering them for diabetes treatment and not for weight management